Flomoxef


Concise Prescribing Info
Indications/Uses
Susceptible infections.
Dosage/Direction for Use
Adult : IV 1-2 g/day, given in 2 divided doses. For severe infection, may be increased to 4 g/day in 2-4 divided doses, adjusted according to severity of condition.
Dosage Details
Intravenous
Susceptible infections
Adult: Usual dose: 1-2 g daily in 2 divided doses. For severe infection, may be increased to 4 g daily in 2-4 divided doses.
Child: Usual dose: 60-80 mg/kg daily in 3-4 divided doses. Newborn infants: 20 mg/kg 2-3 times daily within 3 days of birth, then 3-4 times daily from 4th day after birth. Dose may be increased to 150 mg/kg daily in 3-4 divided doses, adjusted according to severity of condition.
Reconstitution
Add at least 4 mL of water for inj, glucose 5% solution for inj or NaCl 0.9% solution to a vial containing 0.5 g or 10 g. Shake vigorously until solution is dissolved.
Contraindications
Hypersensitivity. History of shock.
Special Precautions
Patient with predisposition to allergic reactions (e.g. bronchial asthma, rash and urticaria), poor oral ingestion, poor general conditions, cardiac or circulatory disorder. Parenterally-fed patients. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Shock, anaphylactoid reactions, vitamin K deficiency, renal dysfunction exacerbation, increased Na and circulatory load, anaemia, eosinophilia, granulocytopaenia, pancytopaenia, thrombocytopaenia, haemolytic anaemia, hepatic dysfunction, jaundice, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous colitis, interstitial pneumonia, pulmonary infiltration with eosinophilia (PIE) syndrome.
Gastrointestinal disorders: Diarrhoea.
Investigations: Increased ALT/AST, increased ɣ-GTP.
Skin and subcutaneous tissue disorders: Rash.
MonitoringParameters
Monitor renal function, LFT, and CBC periodically. Monitor signs and symptoms of hypersensitivity.
Drug Interactions
May exacerbate nephrotoxic effect with diuretics (e.g. furosemide).
Lab Interference
False-positive result in urine sugar test with Benedict’s solution. Positive reactions in direct Coombs’ test.
Action
Description: Flomoxef is an oxacephalosporin, a bactericidal agent. It has affinity to penicillin-binding proteins and prevents action to peptidoglycan-crosslinking enzymes thus inhibiting bacterial cell wall synthesis.
Pharmacokinetics:
Absorption: Time to peak plasma concentration: 6 hours.
Distribution: Well distributed and penetrates moderately into lung, mucosal tissue of the middle ear and bone. Plasma protein binding: 35%.
Metabolism: Minimally metabolised in the liver into active metabolite and inactive hydroxy-ethyltetrazolethiol metabolite.
Excretion: Via urine (80-90% as unchanged drug). Elimination half-life: Approx 50 minutes.
Chemical Structure

Chemical Structure Image
Flomoxef

Source: National Center for Biotechnology Information. PubChem Database. Flomoxef, CID=65864, https://pubchem.ncbi.nlm.nih.gov/compound/Flomoxef (accessed on Jan. 21, 2020)

Storage
Store below 25°C.
MIMS Class
ATC Classification
J01DC14 - flomoxef ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
References
Anon. Flomoxef. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 12/03/2018.

Buckingham R (ed). Flomoxef Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 12/03/2018.

Flomoxef. Gold Standard Drug Database in ClinicalKey [online]. Elsevier Inc. https://www.clinicalkey.com/. Accessed 14/03/2018.

Disclaimer: This information is independently developed by MIMS based on Flomoxef from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in